Head to head
Moderna vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: MRNA · VRTX
MRNA
Moderna
196.48+4.81%
1-year price shape — +619% over the period
Quant Rating A · 100/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| MRNA | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 196.48 | 505.64 |
| Change today | +4.81% | +0.66% |
| 1-year return | +618.7% | +23.2% |
| Market cap | $78.44B | $128.16B |
| 52-week range | 22.28 – 212.22 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -24.62 | 29.45 |
| P/E percentile, own 5-yr range | 0th | 74th |
| P/B | 11.60 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -7.26 | 15.32 |
| Net profit (TTM) | $-2.90B | $3.88B |
| Revenue (TTM) | $2.21B | $12.59B |
| Revenue growth (YoY) | +4.4% | +12.5% |
| Gross margin | 22.8% | 86.0% |
| Operating margin | -150.2% | 37.9% |
| Net margin | -142.6% | 35.0% |
| Free cash flow (TTM) | $-1.24B | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 80.5% | 97.2% |
| Insider activity (12mo) | 22 buy / 27 sell | 25 buy / 25 sell |
| Short interest (% of float) | 8.2% | 1.9% |
| Analyst consensus | 23% buy / 62% hold / 15% sell (13) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $117 (-40%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | A (100) | C (67) |
| Company | ||
| Employees | 4,700 | 6,400 |
| Founded | 2010 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.